ASXL1 mutation as a surrogate marker in acute myeloid leukemia with myelodysplasia-related changes and normal karyotype.

Differences in terms of overall survival between AML‐MRC ASXL1+ versus ASXL1− patients were found only in de novo AML‐MRC patients with intermediate‐risk karyotype (excluding MDS and MDS/MPN history and adverse‐risk karyotype), having ASXL1 + patients a worst outcome with a clear trend toward statistical association than ASXL1 −, HR = 2.9 P = .072 (Figure 3B ).

also in 19,460 other papers

In addition, ASXL1+ patients showed a trend toward a higher presence of megakaryocyte dysplasia (≥50%) in bone marrow.

also in 53,322 other papers